Natural History of Pediatric-onset Inflammatory Bowel Disease A Systematic Review

Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Journal of clinical gastroenterology (Impact Factor: 3.5). 08/2012; 46(7):581-9. DOI: 10.1097/MCG.0b013e318247c32f
Source: PubMed


There has been no systematic review of natural history studies of pediatric-onset inflammatory bowel disease (IBD). We conducted a systematic review focused on understanding the long-term risks of growth failure, disease reclassification and extension, hospitalizations, cancer and death among patients with childhood IBD.
PubMed searches and subsequent data abstraction were performed by 2 independent investigators. Studies published full in english with a 5-year minimum average follow-up in at least 30 patients with IBD onset before age 18 years.
We evaluated 41 total studies (only 2 population-based studies) with 3505 Crohn's disease (CD) patients, 2071 ulcerative colitis (UC) patients, and 461 indeterminate colitis (IC). Growth failure was reported in CD (10% and 56%) more often than UC (0% to 10%) or non-IBD controls. Improvements in growth occurred after surgical resection in patients with CD. There was an increase in disease reclassification over time from UC and indeterminate colitis diagnosis to CD diagnosis. Patients with CD had higher number of hospitalizations and hospital days per year in comparison with UC patients in most studies. The reported surgery rates in CD ranged between 10% and 72%; the colectomy rates in UC ranged between 0% and 50%. Cancers were reported in 6 CD patients during a total 18,270 patient-years (PY) follow-up, and 8 UC patients in 18,115 PY. Deaths directly related to IBD were 63 during 39,719 PY.
Childhood-onset IBD patients had growth failure reported in patients with CD more often than those with UC, had a reclassification of disease type to CD over time. Higher rates of surgery and hospitalizations were found with CD than with UC. The risk of cancer and death is low in this population.

Download full-text


Available from: Bincy P Abraham, Nov 06, 2014
  • Source
    • "The overall prevalence of IBD-indeterminate ranges from 3%–29%.3–6 This figure has not changed over the past 30 years despite the introduction of newer diagnostic modalities.1,2,5–8 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory bowel disease (IBD)-indeterminate is a subgroup of IBD that has features of both ulcerative colitis (UC) and Crohn's disease (CD). To determine the clinical course of IBD-indeterminate in children over a 25 year period. We performed a retrospective investigation on children diagnosed with IBD. Diagnosis and disease distribution of IBD was based on clinical, radiologic, endoscopic, and histologic examinations. Four hundred and twenty children diagnosed with IBD between 1986 and 2003 were identified from the IBD registry, 78 (22%) of whom were diagnosed with IBD-indeterminate. The mean age at diagnosis was 9.2 ± 4 years and the mean follow-up period was 4.1 ± 2 years. In 2003, 18 of 78 children (23%) were reclassified by the same physician based on the endoscopic and pathologic findings as follows: eight children with CD, five children with UC, and five children with non-IBD (eg, eosinophilic colitis). During 2011, 20 of the 60 patients who had maintained an IBD-indeterminate diagnosis were located and contacted, and detailed telephone interviews were conducted by the corresponding author. Two patients were reclassified as having CD (10%), one patient was reclassified as having eosinophilic colitis (5%), six patients remained with IBD-indeterminate (30%), and eleven patients (55%) reported a complete resolution of their symptoms. The follow-up period ranged from 10-18 years (mean 12.5 ± 3 years). Children who were reclassified as having CD were significantly younger than those who maintained an IBD-indeterminate diagnosis (6.4 ± 4 years versus11.2 ± 3 years, respectively, P = 0.05). Children with IBD-indeterminate remain classified as IBD-indeterminate, or were clinically reclassified as CD or non-IBD, or became asymptomatic as they transitioned into adulthood. The need for IBD-indeterminate classification is of importance, especially when deciding on management and treatment.
    Full-text · Article · Jul 2013 · Clinical and Experimental Gastroenterology
  • Source
    • "Understanding the epidemiology of IBD in pediatrics is required to comprehend the natural history of the disease. Several studies have shown rising incidence of pediatric Crohn’s disease (CD) over the last several years; however, the incidence of ulcerative colitis (UC) has remained stable or marginally decreased.1–9 UC disease has an early onset; children could be at high risk of disease complications, surgery, and develop extraintestinal manifestations (EIMs). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The natural history of ulcerative colitis (UC) has been poorly studied in children. We performed a retrospective study in children diagnosed with UC with a follow-up. The diagnosis of UC was based on clinical, radiologic, endoscopic, and histologic examinations. We estimated the occurrence of colectomy, proctitis, and extraintestinal manifestations (EIMs) at the onset of the diagnosis and at the end of the study period. We identified 115 UC patients between 1986 and 2003 with a mean age at diagnosis of 10.6 ± 5.1 years. The cumulative rate of colectomy was 4.1% at 1 year, and 16% at 10 years. EIMs were experienced by 20% of the children; 48% had arthritis, 35% had sclerosing cholangitis, and 17% had aphthous stomatitis. Proctitis was noted in 29 patients and it was not associated with an increased risk of colectomy (relative risk = 1.4; 95% CI = 0.7-4.5), and girls were twice more likely to develop proctitis. The pathologic reading for disease extensions was recorded for all children at entry and only 62 children had pathological results at maximum follow-up. At entry, 25% of the children only had ulcerative proctitis (E1) localization, 40% had left-sided UC (E2), and 35% had extensive UC (E3). Among the patients with E1 localization, 20% had progressed to E2 and 80% had progressed to E3; among the patients with E2 localization, 40% had progressed to E3. Age, gender, and EIMs at time of diagnosis were not associated with extension of disease at maximal follow-up. The Z score of body mass index (BMI) of children was significantly higher at the end of the study. At diagnosis, 85% of patients received 5-aminosalicyclic acid, 60% received steroids, and 11% received an immunomodulator. The majority of patients were still using systemic steroids at and after 5 years from their entry date. Only 32 of the 91 children on steroids did not receive an immunomodulator. Pediatric UC is associated with high rates of EIMs and colectomy that are not dependent on age, gender, or race, but is associated with a high rate of proctitis among girls. Understanding the clinical course of UC can optimize therapeutic interventions.
    Full-text · Article · Jun 2013 · Clinical and Experimental Gastroenterology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Crohn's disease (CD) is diagnosed in about 20 % of patients before the age of 18 years. Its phenotype is more complicated than in adult-onset CD and requires more aggressive therapy, including surgery. Surgery rates in pediatric CD range between 10 and 72 %. Indications for surgery include medically refractory disease (especially with growth failure) and complicated behaviour. Surgery is crucial, allowing children to catch up in growth and height before late puberty. However, surgery is not curative and post-operative recurrence (POR) is almost inevitable. Even if pediatric data are scarce, clinical recurrence has been reported in 50-94 % and re-operation in 18-54 % of cases, depending on the follow-up time. Thus, prevention of POR has a decisive role in managing CD. Several strategies have been used to decrease POR, with only some being efficacious and not in all cases. Therefore, currently, no standard of care for the management of postoperative CD does exist. The published studies in adults, systematic reviews and meta-analyses have shown efficacy for thiopurines, nitroimidazole antibiotics and anti-TNFα agents, while budesonide, probiotics and interleukin-10 were not effective. Although safe, mesalazine is of little benefit and not recommended, except in few selected patients. Since no randomized-controlled trial has been performed in children, data have to be extrapolated from adults and enteral nutrition may play an important role. In the prevention of recurrence, it is imperative to consider its risk factors, how it should be assessed, and what medication to use in relation to risk factors and cost-efficacy, based on actual evidence.
    Full-text · Article · Jan 2013
Show more